Clinical Trials Browser

Carcinoma, Carcinoma, Renal Cell

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-02-19

MK-3475-03C

Phase 1/2 Recruiting

140 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

80 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Phase 2 Recruiting

10 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

Clinical Trials

LITESPARK-033

MK-6482-015

MK-3475-03C

KEYNOTE-365

MK-3475-03A

MK-6482-043

MK-6482-024

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

LITESPARK-029